GSK4347859
/ GSK
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
October 04, 2025
A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing With GSK4347859 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=65 | Suspended | Sponsor: GlaxoSmithKline | Trial completion date: Mar 2026 ➔ Jul 2026 | Recruiting ➔ Suspended | Trial primary completion date: Mar 2026 ➔ Jul 2026
Trial completion date • Trial primary completion date • Trial suspension • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
April 25, 2025
A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing With GSK4347859 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=65 | Recruiting | Sponsor: GlaxoSmithKline | N=49 ➔ 65
Enrollment change • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
September 27, 2024
A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing With GSK4347859 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=49 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting | Trial completion date: Mar 2025 ➔ Apr 2026
Enrollment open • Trial completion date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
January 03, 2024
A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing With GSK4347859 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=44 | Not yet recruiting | Sponsor: GlaxoSmithKline
New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
1 to 4
Of
4
Go to page
1